Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 3
CDK4 (Cyclin-Dependent Kinase 4) and CDK6 (Cyclin-Dependent Kinase 6) are crucial regulators of the cell cycle, specifically involved in the transition from the G1 phase to the S phase. These kinases form complexes with D-type cyclins (Cyclin D1, D2, and D3), which are necessary for their activation. Once activated, CDK4 and CDK6 phosphorylate the retinoblastoma protein (RB1), leading to the release of E2F transcription factors that drive the expression of genes required for DNA synthesis and cell cycle progression. Dysregulation of CDK4 and CDK6 activity is a common feature in various cancers, as it can lead to uncontrolled cell proliferation. Consequently, CDK4 and CDK6 have become important targets in cancer therapy, with inhibitors such as palbociclib, ribociclib, and abemaciclib being developed and approved for the treatment of certain types of cancer, particularly hormone receptor-positive breast cancer. These inhibitors work by blocking the kinase activity of CDK4 and CDK6, thereby halting cell cycle progression and reducing tumor growth.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
蛋白别名:
Cell division protein kinase 4; Cell division protein kinase 6; CR2 protein kinase; CRK2; CRK3; cyclin dependent kinase 4; Cyclin-dependent kinase 4; Cyclin-dependent kinase 6; p34
基因别名: 5830411I20; AI504062; CDK4; CDK6; CDKN6; CMM3; Crk2; Crk3; MCPH12; PLSTIRE; PSK-J3
UniProt ID: (Human) P11802, (Human) Q00534, (Rat) P35426, (Mouse) P30285, (Mouse) Q64261
Entrez Gene ID: (Human) 1019, (Human) 1021, (Rat) 94201, (Mouse) 12567, (Rat) 114483, (Mouse) 12571